Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model

Area of Science:

• Oncology
• Bone Biology
• Radiopharmaceuticals

Background:

• Multiple myeloma (MM) is characterized by osteolytic bone disease, driven by MM cell proliferation and altered bone cell activity.
• Bortezomib, a proteasome inhibitor, targets MM cells and shows bone-protective effects.
• Radium-223 dichloride (radium-223) is an alpha therapy targeting bone metastases, impacting tumor and bone cells.

Purpose of the Study:

• To investigate the potential additive effects of combining radium-223 and bortezomib for treating multiple myeloma.
• To evaluate the efficacy of this combination therapy on MM cell proliferation and bone disease in vitro and in vivo.

Main Methods:

• In vitro studies assessed the impact of combination therapy on MM cell proliferation.
• In vivo studies utilized a syngeneic 5TGM1 mouse model of MM.
• Evaluated osteolytic lesion area, osteoclast numbers, tumor burden, and body weight changes.

Main Results:

• Combination therapy demonstrated additive efficacy in inhibiting MM cell proliferation in vitro.
• In vivo, both bortezomib and radium-223 reduced osteolytic lesions; the combination was superior to monotherapy.
• Combination treatment led to near-complete osteoclast eradication, improved radium-223 bone incorporation, decreased tumor burden, and restored body weight.

Conclusions:

• The combination of radium-223 and bortezomib shows significant promise as a novel therapeutic strategy for multiple myeloma.
• This combination therapy is particularly effective against myeloma bone disease, offering a new treatment avenue.